瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06938 瑞博生物-B

未开盘 04-15 16:08:06

71.000

+2.250

+3.27%

最高74.500	最低69.050	成交量94.27万
今开69.050	昨收68.750	日振幅7.93%
总市值121.09亿	流通市值121.09亿	总股本1.71亿
成交额6,839万	换手率0.55%	流通股本1.71亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"瑞博生物-B","latestPrice":71,"timestamp":1776240486911,"preClose":68.75,"halted":0,"volume":942734,"delay":0,"changeRate":0.03272727272727273,"floatShares":170554910,"shares":170554910,"eps":-2.100221,"marketStatus":"未开盘","change":2.25,"latestTime":"04-15 16:08:06","open":69.05,"high":74.5,"low":69.05,"amount":68391770,"amplitude":0.079273,"askPrice":71.05,"askSize":200,"bidPrice":71,"bidSize":1600,"shortable":0,"etf":0,"ttmEps":-1.805,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776303000000},"marketStatusCode":0,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":68.75,"openAndCloseTimeList":[[1776216600000,1776225600000],[1776229200000,1776240000000]],"volumeRatio":3.982587,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06938","defaultTab":"news","newsList":[{"id":"2627472360","title":"港股异动 | 瑞博生物-B(06938)早盘涨超7% Vortosiran房颤卒中预防IIb期申请成功递交","url":"https://stock-news.laohu8.com/highlight/detail?id=2627472360","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627472360?lang=zh_cn&edition=full","pubTime":"2026-04-15 11:29","pubTimestamp":1776223751,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞博生物-B早盘涨超7%，截至发稿，涨6.04%，报72.9港元，成交额1172.61万港元。随着Vortosiran针对冠状动脉疾病的IIa期试验的完成，本次申报将进一步巩固和加强该产品作为全球最快的FXI靶向小核酸药物的领先地位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4588","06938","BK4585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627464707","title":"瑞博生物-B(06938)：核心产品VORTOSIRAN完成针对SPAF适应症的 2b期临床试验申请递交","url":"https://stock-news.laohu8.com/highlight/detail?id=2627464707","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627464707?lang=zh_cn&edition=full","pubTime":"2026-04-14 08:02","pubTimestamp":1776124949,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B 发布公告，本公司核心产品Vortosiran 已成功向欧洲药品管理局递交针对心房颤动患者卒中预防 的2b期临床试验申请，这是全球首个于心房颤动临床试验中的小干扰核酸 XI凝血因子抑制剂，标志着siRNA药物在抗凝疗法领域临床开发的重要里程碑。本研究为本公司涵盖多个已规划的针对多种血栓栓塞性心血管适应症的2b期研究的一部分。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428030.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130944510","title":"瑞博生物-B3月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1130944510","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130944510?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:47","pubTimestamp":1775724461,"startTime":"0","endTime":"0","summary":"瑞博生物-B于2026年4月9日发布截至2026年3月31日的股份变动月报表。公告显示，公司注册股本维持人民币170,554,910元，报告期未见新增发行、回购或注销股份活动。至本月底，已发行股份总数与上月底持平，均为170,554,910股。\n报告提到，公司现有2,113,987份期权，行使价为每股人民币3.70元，最早归属日期为2028年1月9日，当前尚未有任何期权实际行使或归属。公司当前符合港交所关于公众持股量的要求，最低公众持股量百分比为15.61%。\n据公告，公司的所有股份及相关发行活动均获得董事会正式授权批准，并遵守相关上市规则和法律规定。该月报表由公司联席公司秘书张甦签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624314016","title":"中金：国产创新药产业趋势向好 26年学术领域看点较多","url":"https://stock-news.laohu8.com/highlight/detail?id=2624314016","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624314016?lang=zh_cn&edition=full","pubTime":"2026-04-03 10:41","pubTimestamp":1775184094,"startTime":"0","endTime":"0","summary":"中金主要观点如下：研发效率、临床资源优势禀赋，国产创新BD加速、量价齐升NMPA和医药魔方统计显示，2026Q1国内创新药BD总金额超600亿美元，超过2024全年、接近2025全年水平1/2；且平均首付款和平均交易规模均创历史新高。在MNC的积极推动下，多个中国创新资产有望在2026年步入上市申报阶段；基于对国内企业创新能力的认可，多个早期平台化对外合作交易陆续达成。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424995.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2778985437.USD","159992","06978","BK1515","LU1303224171.USD","01276","01877","LU2328871848.SGD","LU0561508036.HKD","06938","LU0634319403.HKD","LU2543165471.USD","LU0348783233.USD","LU0359202008.SGD","LU0359201885.HKD","LU0588546209.SGD","LU0348766576.USD","BK1500","09995","LU1023057109.AUD","LU0348784397.USD","LU1961090484.USD","LU1969619763.USD","LU2476274720.SGD","IE00B5MMRT66.SGD","BK1191","BK1583","LU0540923850.HKD","LU0359201612.USD","LU0348825331.USD","LU1720050803.USD","LU1770034418.SGD","IE00B543WZ88.USD","LU0417516902.SGD","LU2488822045.USD","BK1161","09926","06160","LU0348767384.USD","LU1719994722.HKD","IE00BPRC5H50.USD","LU2399975544.HKD","LU0417516738.SGD","LU0417516571.SGD","BK1588","BK1574","LU0348827113.USD","LU1794554557.SGD","LU0348735423.USD","LU0307460666.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622511077","title":"瑞博生物-B(06938)拟采纳H股购股权计划及H股激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2622511077","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622511077?lang=zh_cn&edition=full","pubTime":"2026-03-25 22:50","pubTimestamp":1774450252,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B(06938)发布公告，于2026年3月25日，董事会议决建议采纳本公司H股购股权计划(H股购股权计划)及H股激励计划(H股激励计划，统称为“股份计划”)，惟须待本公司股东批准后，方可作实。股份计划旨在为合资格人士(包括雇员参与者、服务提供者及相关实体参与者)提供获得本公司专有权益的机会，藉以鼓励合资格人士为本公司及股东的整体利益积极工作，提升本公司及本公司股份的价值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419099.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622072754","title":"瑞博生物-B(06938)：Anders Gabrielsen获委任为公司首席医学官","url":"https://stock-news.laohu8.com/highlight/detail?id=2622072754","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622072754?lang=zh_cn&edition=full","pubTime":"2026-03-25 22:38","pubTimestamp":1774449502,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B(06938)发布公告，Anders Gabrielsen博士已获委任为公司首席医学官，将负责公司的整体临床开发、医学事务及监管合规;John Taylor博士已获委任为公司首席商务官，将负责公司的整体商务发展、授权引进及对外许可合作以及战略投资;甘黎明博士不再担任首席医学官，但将继续担任公司的执行董事、联席首席执行官兼全球研发总裁，均自2026年3月25日起生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419085.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622756072","title":"瑞博生物-B(06938)2025年实现收入约1.485亿元，同比增加4.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622756072","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622756072?lang=zh_cn&edition=full","pubTime":"2026-03-25 22:35","pubTimestamp":1774449346,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B 公布2025年业绩，收入约1.485亿元，同比增加4.1%。毛利约1.35亿元，同比增加3.3%。研发开支约2.8亿元，基本持平。公告称，收入增长主要是由于勃林格殷格翰合作及兴博润销售核苷单体相关产品所产生的收入增加所致。自成立以来，公司已分别与勃林格殷格翰及齐鲁制药订立多项许可及合作协议，总交易价值超过21亿美元。根据有关协议，公司已授予Madrigal开发、生产及商业化若干siRNA资产的独家全球许可。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618138477","title":"瑞博生物-B(06938.HK)拟3月25日举行董事会会议以审批年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2618138477","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618138477?lang=zh_cn&edition=full","pubTime":"2026-03-12 18:07","pubTimestamp":1773310024,"startTime":"0","endTime":"0","summary":"格隆汇3月12日丨瑞博生物-B(06938.HK)公告，董事会会议将于2026年3月25日(星期三)举行，藉以(其中包括)考虑及批准集团截至2025年12月31日止年度业绩及其发布，并考虑建议派发末期股息(如有)及处理其他事务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260312/32063755.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113065955","title":"瑞博生物-B（06938）更新2026年2月股份变动月报表，股本增至170,554,910股","url":"https://stock-news.laohu8.com/highlight/detail?id=1113065955","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113065955?lang=zh_cn&edition=full","pubTime":"2026-03-05 17:40","pubTimestamp":1772703632,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年3月5日披露2026年2月股份变动月报。报告期为2026年2月1日至2026年2月28日。根据公告披露，已发行股份自上月底的165,813,510股增加4,741,400股至170,554,910股，法定/注册股本由人民币165,813,510元增至人民币170,554,910元。报告显示，现有2,113,987份尚未行使的期权，行使价为每股人民币3.70元，截至2028年1月9日方可开始行使。截至2026年2月28日，公司总股本数量变动后为170,554,910股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617000516","title":"花旗：首予瑞博生物-B(06938)“买入”评级 目标价102港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617000516","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617000516?lang=zh_cn&edition=full","pubTime":"2026-03-05 15:17","pubTimestamp":1772695058,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发表研究报告指，瑞博生物-B(06938)是siRNA领域的龙头企业，拥有具差异化药物管线、领先的药物递送技术平台等核心优势。该行认为，瑞博生物的核心候选药物RBD4059，有望成为治疗血栓性疾病的突破性药物，该药销售潜力可达超过60亿美元，而该潜力被市场低估。该行首予公司“买入”评级，目标价102港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410395.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616043374","title":"瑞博生物-B03月03日主力净流出70.8万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2616043374","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616043374?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:15","pubTimestamp":1772525757,"startTime":"0","endTime":"0","summary":"03月03日, 瑞博生物-B股价跌5.06%，报收61.00元，成交金额1771.5万元，换手率0.17%，振幅9.26%，量比1.30。瑞博生物-B今日主力资金净流出70.8万元，上一交易日主力净流入1308.1万元。该股近5个交易日下跌14.69%，主力资金累计净流入3623.3万元；近20日主力资金累计净流入3419.2万元，其中净流入天数为4日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303162109a445bbc0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303162109a445bbc0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165985607","title":"瑞博生物-B启动RBD7022注射液治疗高脂血症III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1165985607","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165985607?lang=zh_cn&edition=full","pubTime":"2026-03-02 08:11","pubTimestamp":1772410268,"startTime":"0","endTime":"0","summary":"瑞博生物-B（股票代码：06938）近日宣布，其研发的RBD7022注射液将在中国正式启动针对高脂血症治疗的III期临床试验。该试验旨在进一步评估该药物在更广泛患者群体中的安全性与有效性，标志着其在心血管代谢疾病治疗领域的研发进程迈入关键阶段。高脂血症作为常见的心血管风险因素，其创新疗法的推进备受市场关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616877702","title":"瑞博生物-B(06938)：RBD7022注射液即将于中国启动用于治疗高血脂症适应症的 III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2616877702","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616877702?lang=zh_cn&edition=full","pubTime":"2026-03-02 08:11","pubTimestamp":1772410260,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B(06938)公布，集团自主研发的RBD7022注射液已由合作方齐鲁制药有限公司(齐鲁制药)完成III期临床试验登记公示，即将启动III期临床试验。RBD7022注射液是一款靶向PCSK9的siRNA药物。PCSK9是一种酶，在调节体内胆固醇，尤其是通常被称为“LDL-C”或“坏胆固醇”的低密度脂蛋白(LDL)胆固醇的水平方面起关键作用，可作为管理高胆固醇血症的一种治疗选择，旨在降低与高胆固醇水平相关的心血管疾病风险。2023年12月，公司将RBD7022注射液在中国内地、中国香港和中国澳门开发、生产和商业化的独家权利授予齐鲁制药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408738.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK1161","06938","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614869918","title":"瑞博生物-B02月27日主力净流入2386万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2614869918","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614869918?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:15","pubTimestamp":1772180151,"startTime":"0","endTime":"0","summary":"02月27日, 瑞博生物-B股价涨1.93%，报收68.50元，成交金额2687.6万元，换手率0.23%，振幅2.98%，量比3.18。瑞博生物-B今日主力资金净流入2386万元，上一交易日主力净流出0万元。该股近5个交易日下跌5.45%，主力资金累计净流入2386万元；近20日主力资金累计净流入1868.0万元，其中净流入天数为3日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227161942a4cefda1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227161942a4cefda1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614699958","title":"中邮证券：siRNA药物机制优势突出 递送为核心技术","url":"https://stock-news.laohu8.com/highlight/detail?id=2614699958","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614699958?lang=zh_cn&edition=full","pubTime":"2026-02-27 11:04","pubTimestamp":1772161440,"startTime":"0","endTime":"0","summary":"中邮证券发布研报称，siRNA药物可精准沉默致病蛋白，优势显著，递送系统为核心技术。海外巨头基于GalNAc肝递送平台，针对心血管靶点的药物已进入收获期。中邮证券主要观点如下：siRNA药物机制优势突出，递送为核心技术相较于传统小分子和生物药，siRNA药物为代表的核酸疗法可精准沉默致病蛋白，高效降解且作用时间长，目前已成为新药开发热门方向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227120913a72505ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227120913a72505ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06938","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614772030","title":"国泰海通：FXI引领抗凝药产业新变革 多技术路线竞逐蓝海","url":"https://stock-news.laohu8.com/highlight/detail?id=2614772030","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614772030?lang=zh_cn&edition=full","pubTime":"2026-02-25 13:37","pubTimestamp":1771997868,"startTime":"0","endTime":"0","summary":"FXI开启抗凝新时代，多技术路线竞逐蓝海研究表明，凝血因子XI是推动病理性血栓的重要因子，但在大多数情况下对正常止血并非必需，比如具有遗传性FXI缺乏的人群，血栓事件的发生率明显降低，而自发性出血的风险并未显著增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0183","BK1147","BK1191","LU2543165471.USD","BK0276","BK1564","BK1161","BK0012","LU0359201612.USD","LU0359202008.SGD","BK0184","02611","LU1023057109.AUD","BK0028","06938","LU0359201885.HKD","601211","BK0201","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612230236","title":"中金：首予瑞博生物-B(06938)“跑赢行业”评级 目标价100港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2612230236","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612230236?lang=zh_cn&edition=full","pubTime":"2026-02-20 09:58","pubTimestamp":1771552683,"startTime":"0","endTime":"0","summary":"截至25年底，公司已拥有7款进入临床阶段的siRNA管线，其中4款处于II期，RBD4059(FXI)、RBD5044(ApoC3)、RBD1016(HBV)是核心资产。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260220/20260220094929_32902.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260220/20260220094929_32902.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1405976.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2611165746","title":"2026年中国生物科技授权交易将迎爆发式增长，有望创历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2611165746","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611165746?lang=zh_cn&edition=full","pubTime":"2026-02-13 17:05","pubTimestamp":1770973500,"startTime":"0","endTime":"0","summary":"全球制药企业在专利到期前纷纷削减成本，正加大力度寻找中国研发的创新候选药物，行业分析师预计，今年相关授权交易规模将飙升至历史新高。2026 年至今已宣布38 笔对外授权交易；2025 年全年为186 笔。行业咨询机构 Vision Lifesciences 在 2026 年生物科技授权展望中称，中国在抗体药物偶联物领域全球领先，相关授权交易占全球近90%。首付款大幅上涨随着交易规模扩大，全球药企获取中国药物开发权所需支付的首付款也大幅飙升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213182820a6f7567b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213182820a6f7567b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938","BK1161","01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611165798","title":"近 60 亿美元！不到十天两起小核酸授权出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2611165798","media":"医麦客","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611165798?lang=zh_cn&edition=full","pubTime":"2026-02-13 07:20","pubTimestamp":1770938451,"startTime":"0","endTime":"0","summary":"根据协议条款，瑞博生物将授予 Madrigal 多款 MASH 领域单靶点及双靶点临床前 siRNA 资产的全球独家研发、生产与商业化权利。Madrigal 的 THR-β 激动剂已经获批上市，用于治疗 MASH，2025 年前三季度销售额 6.4 亿美元，预计全年超过 10 亿美元。这是瑞博生物肝靶向 RiboGalSTAR 平台第二次达成重磅出海合作。早在 2023 年，瑞博生物就此平台与勃林格殷格翰达成共同开发治疗 MASH 的小核酸创新疗法的合作，合作总额超 20 亿美元，成为国内首个向 MNC 许可的 RNAi 技术平台。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021307240697a5ffdf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021307240697a5ffdf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610915655","title":"瑞博生物-B(06938)因悉数行使超额配股权发行474.14万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2610915655","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610915655?lang=zh_cn&edition=full","pubTime":"2026-02-12 14:11","pubTimestamp":1770876660,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B(06938)发布公告，于2026年2月10日根据悉数行使超额配股权而发行及配发474.14万股H股股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ribolia.com","stockEarnings":[{"period":"1week","weight":0.0411},{"period":"1month","weight":0.2075},{"period":"3month","weight":-0.0664},{"period":"6month","weight":0.2248},{"period":"ytd","weight":0.2248}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":0.0044},{"period":"3month","weight":-0.0363},{"period":"6month","weight":0.0277},{"period":"1year","weight":0.2087},{"period":"ytd","weight":0.0124}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"苏州瑞博生物技术股份有限公司是一家主要从事小核酸药物研究和开发，尤其专注于小干扰核酸（siRNA）疗法的中国公司。该公司的主营业务是从事小核酸药物的创新，专注于心血管、代谢类、肾脏和肝病以及其他治疗领域。该公司的药物管线包括RBD4059、RBD5044、RBD7022、RBD7007、RBD2080、RBD1119、RBD1016等。该公司主要在中国国内市场开展业务。","exchange":"SEHK","name":"瑞博生物-B","nameEN":"RIBOLIFE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供瑞博生物-B(06938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"瑞博生物-B,06938,瑞博生物-B股票,瑞博生物-B股票老虎,瑞博生物-B股票老虎国际,瑞博生物-B行情,瑞博生物-B股票行情,瑞博生物-B股价,瑞博生物-B股市,瑞博生物-B股票价格,瑞博生物-B股票交易,瑞博生物-B股票购买,瑞博生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供瑞博生物-B(06938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}